Case Reports That Illustrate the Efficacy of SGLT2 Inhibitors in the Type 1 Diabetic Patient

Table 1

Characteristics of type 1 diabetic patients before SGLT2 therapy.

Patient	Age in years	Gender	Duration of diabetes (years)	eGFR mls/min	Total daily insulin dose and type
1	33	Female	16	97	Detemir 15 units
					Lispro 10 units
2	63	Female	23	64	Glargine 40 units
					Lispro 12 units
3	68	Male	35	65	Detemir 54 units
					Aspart 10 units
4	44	Male	26	42	Glargine 80 units
					Aspart 300 units
5	42	Female	28	84	Aspart 50 units by insulin pump